Glycoprotein-based Vaccine Development

Glycoprotein-based Vaccine Development

CD BioGlyco provides one-stop custom services for glycoprotein-based vaccine development to meet customers' research needs. We are confident to be your essential research assistant in the field of glycobiology.

Examples of Glycoprotein-based Vaccine Development

Rabies virus glycoprotein (RVGP) is the only antigen exposed on the surface of virus particles, which can induce the host to produce neutralizing antibodies. It is also the only viral component present in all new rabies vaccines. Many studies have expressed the immunogenic recombinant rabies virus glycoprotein (rRVGP) and related research on the similarity between it and natural RVGP in structure and in stimulating the body's immune response, providing research ideas for new rabies genetic engineering vaccines.

The hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are critical in virus attachment and cell fusion, and the study of these proteins may provide valuable insights into their potential use in vaccines and antiviral strategies. The immunogenicity of E1 and E2 has led to various ongoing attempts to develop one or two envelope glycoproteins into vaccines.

Human herpesvirus 6B (HHV-6B) is a pathogen that infects most babies with fever and persistent sequelae, such as inflammation of the brain, but effective methods for preventing or treating HHV-6B infection have not been established. Some researchers have previously discovered the HHV-6B glycoprotein complex, which is an important factor in HHV-6B infection. They used this complex as a vaccine antigen and analyzed its effectiveness, hoping it will protect infants from the virus.

 Fig. 1 Hepatitis C E1 and E2 glycoprotein structures.Fig.1 Hepatitis C E1 and E2 glycoprotein structures. (Sepulveda-Crespo, 2020)

Our Solutions

CD BioGlyco has developed highly specialized platforms and various systematic and innovative solutions for the design, expression or synthesis of glycoprotein vaccine candidates.

  • We have established glyco-engineered yeast systems, plant systems, insect cell systems, mammalian cell systems, and viral vector systems to express immunogenic glycoproteins. Related research on the similarities between them and the natural antigen in structure and stimulating the body's immune response can be carried out and will provide ideas for a new type of rabies genetic engineering vaccine.
  • Site-specific glycosylation methods can solve the problem of heterogeneous glycoform of glycoprotein vaccine candidates. Site-specific strategies allow the synthesis of glycoproteins with precisely controlled epitopes. We have chemical and chemoenzymatic platforms to perform site-specific glycosylation, and to ensure that the highly purified homogeneous glycoprotein vaccine candidates obtained are efficiently and simply operated under mild conditions.
  • We also provide customized glycoprotein remodeling services, which can use natural chemical linkage (NCL), expressed protein ligation (EPL), and chemoenzymatic methods to obtain glycoproteins of interest.

Advantages of Us

  • The product has strong immunogenicity and stable quality
  • Multiple stable expression systems
  • Fast speed, short experiment period
  • Comprehensive vaccine process quality assessment system
  • Customize experimental programs according to different research needs
  • Design, production, and inspection one-stop service

CD BioGlyco provides an integrated solution from glycoprotein vaccine design, expression or synthesis, to quality control. For decades, we have won the trust of global scientists with high-quality products, services, and technical support. In terms of vaccine development, our company has unique and advanced technology platforms. Excellent researchers and sophisticated instruments have become our powerful assistance, and we will assist you in your vaccine development process. If you are interested in our services, please contact us for more detailed information.


  1. Sepulveda-Crespo, D.; et al. Hepatitis C virus vaccine design: focus on the humoral immune response. Journal of Biomedical Science. 2020, 27(1).
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.